Balaxi Pharma Receives WHO-GMP Certification for Jadcherla Facility
Balaxi Pharmaceuticals Limited received WHO-GMP Certification for its Jadcherla, Hyderabad facility. The certification, valid until August 26, 2029, was issued by the Government of Telangana following a July 14, 2026 inspection. This milestone strengthens the company's manufacturing and quality credentials for international markets.
The WHO-GMP certification is a significant milestone that strengthens the company's credentials and enables it to expand its product portfolio for international markets, which is expected to have a medium-term impact on operations and growth.
The receipt of WHO-GMP certification is a positive development for the company, enhancing its manufacturing capabilities and market access for international markets.
Balaxi Pharmaceuticals Limited has received the WHO-GMP (Good Manufacturing Practices) Certification for its first pharmaceutical formulation manufacturing facility located in Jadcherla, Hyderabad, Telangana. The certification was issued by the Licensing Authority, Government of Telangana, following an inspection on July 14, 2026. The certificate, dated August 27, 2026, is valid until August 26, 2029.
This certification is a significant milestone for the company, enhancing its manufacturing capabilities and quality credentials. Balaxi Pharmaceuticals has commenced manufacturing of its initially approved products at the facility and plans to progressively add more products for its target international markets, subject to regulatory approvals. The company anticipates no adverse impact on its existing business operations.
A plain-language summary of a public exchange filing by BALAXI PHARMACEUTICALS LIMITED. Read the original for the full detail.